CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30 August 2024 - 10:00PM
CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical
biopharmaceutical company focused on developing and commercializing
a potential backbone bladder-sparing therapeutic for patients with
bladder cancer, today announced that Arthur Kuan, Chairman &
Chief Executive Officer, is scheduled to participate in a fireside
chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.
Interested parties can access the live audio
webcast for this conference from the Investor Relations section of
the company's website at www.cgoncology.com. The webcast replay
will be available after the conclusion of the live presentation for
approximately 90 days.
About CG OncologyCG Oncology is
a late-stage clinical biopharmaceutical company focused on
developing and commercializing a potential backbone bladder-sparing
therapeutic for patients afflicted with bladder cancer. CG Oncology
sees a world where urologic cancer patients may benefit from our
innovative immunotherapies to live with dignity and have an
enhanced quality of life. To learn more, please visit:
www.cgoncology.com.
Contacts
MediaSarah ConnorsVP, Communications and
Patient Advocacy(508) 654-2277sarah.connors@cgoncology.com
Investor RelationsLaurence WattsNew Street
IR(619) 916-7620IR@cgoncology.com
CG Oncology (NASDAQ:CGON)
Historical Stock Chart
From Aug 2024 to Sep 2024
CG Oncology (NASDAQ:CGON)
Historical Stock Chart
From Sep 2023 to Sep 2024